Drug R&D for a cure
Shenzhen Vaccine Biopharmaceuticals Limited was founded by Zhengzhou Viri Biotechnology Limited and the investment fund in Mar of 2022. The company mainly works on the drug/vaccine development for cancer immunotherapy and viral infection.
Vaccine Biopharm is led by Prof. Zhiqiang Han (retired from Zhengzhou University), the co-founder as well as the CEO. The research group is formed by scientists on molecular biology, oncology, pharmaceutical science, organic synthesis. One major work is the next generation of TLR7/8 agonist. The first drug candidate VB6893 is TLR7/8 agonist with prodrug-like feature for enhanced safety profile. VB6893 is currently in the preclinical phase and would be submitted for IND application by the end of 2024.
Drug development pipeline